Loading clinical trials...
Loading clinical trials...
A Phase IIb, Multicentre, Randomised, Double Blind, Placebo Controlled, Three-arm Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability at Week 24 of 2 Doses of CHF10067 (Zampilimab), With an Optional 24-week Double Blind, Placebo Controlled Extension Phase in Participants With Idiopathic Pulmonary Fibrosis
Conditions
Interventions
CHF10067
CHF10067
+1 more
Start Date
June 1, 2026
Primary Completion Date
February 12, 2028
Completion Date
February 12, 2028
Last Updated
April 8, 2026
NCT06238622
NCT07299695
NCT07466420
NCT06241560
NCT07407543
NCT07284459
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions